Microsoft Commits $18 Billion to Expand AI and Cloud Infrastructure in Australia 
U.S. Sanctions Target Chinese Refinery Over Iranian Oil Purchases 
Hyundai Plans 20 New Models in China to Boost EV Strategy and Market Share 
Daiichi Sankyo Stock Drops After Earnings Delay and Oncology Review 
Florida Launches Criminal Probe Into OpenAI Over FSU Shooting Incident 
Meta Expands AI Training With Employee Activity Tracking Tools 
Florida Investigates OpenAI and ChatGPT Over Alleged Role in FSU Shooting 
Brazil Blocks Prediction Market Platforms, Tightens Derivatives Trading Rules 
Nvidia Pushes 800V Data Center Power Systems to Boost Efficiency and Cut Costs 
Why Global Web3 Projects Can't Afford to Skip South Korea: TokenPost Unveils Data-Driven Entry Solutions 
Tesla Earnings Beat Expectations as EV Growth Holds Amid Robotics and AI Shift 
Kakaku.com Stock Surges on EQT Takeover Interest Amid Rising Japan Deal Activity 
Judge Dismisses Elon Musk’s Fraud Claims Against OpenAI, Trial to Proceed on Remaining Allegations 
SK Hynix Reports Record Q1 Profit Surge Driven by AI Memory Chip Demand 
European Car Sales Surge in March as EV and Hybrid Demand Accelerates 
LG Innotek Stock Hits Record High on $68M Automotive Wi-Fi 7 Deal 
Amazon Stock Rises as Meta Expands AWS Partnership for AI Infrastructure 
PHILADELPHIA and OXFORD, United Kingdom, March 02, 2016 -- Adaptimmune Therapeutics plc (Nasdaq:ADAP), a leader in the use of TCR engineered T-cell therapy to treat cancer, today announced that James Noble, Chief Executive Officer of Adaptimmune, will present at Cowen and Company’s 36th Annual Health Care Conference on Monday, March 7th at 4:40 PM (9:40 PM GMT). The conference is being held at the Boston Marriott Copley Place, in Boston, MA.
Adaptimmune’s presentation will be webcast live for investors through the investor section of www.adaptimmune.com and available for a period of 30 days following the conference.
About Adaptimmune
Adaptimmune is a clinical stage biopharmaceutical company focused on novel cancer immunotherapy products based on its T-cell receptor (TCR) platform. Established in 2008, the company aims to utilize the body’s own machinery - the T-cell - to target and destroy cancer cells by using engineered, increased affinity TCRs as a means of strengthening natural patient T-cell responses. Adaptimmune’s lead program is an affinity enhanced T-cell therapy targeting the NY-ESO cancer antigen. Its NY-ESO TCR affinity enhanced T-cell therapy has demonstrated signs of efficacy and tolerability in Phase 1/2 trials in solid tumors and in hematologic cancer types, including synovial sarcoma and multiple myeloma. Adaptimmune has a strategic collaboration and licensing agreement with GlaxoSmithKline for the development and commercialization of the NY-ESO TCR program. In addition, Adaptimmune has a number of proprietary programs. The company has identified over 30 intracellular target peptides preferentially expressed in cancer cells and is currently progressing 12 through unpartnered research programs. Adaptimmune has over 200 employees and is located in Oxfordshire, U.K. and Philadelphia, USA. For more information: http://www.adaptimmune.com.
Adaptimmune Contacts Will Roberts Vice President, Investor Relations T: (215) 825-9306 E: [email protected] Margaret Henry Head of PR T: +44 (0)1235 430036 Mob: +44 (0)7710 304249 E: [email protected]
